Unknown

Dataset Information

0

Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine.


ABSTRACT: BACKGROUND: Mumps outbreaks in populations with high 2-dose measles-mumps-rubella (MMR) vaccine coverage raise the question whether a third dose of MMR vaccine (MMR3) is needed. However, data on the immunogenicity of MMR3 are limited. We assessed mumps virus neutralizing antibody levels pre- and post-MMR3 in a nonoutbreak setting. METHODS: Mumps antibody titers were assessed at baseline, 1 month, and 1 year after MMR3 in subjects aged 18-28 years. RESULTS: At baseline, 5 of 656 (0.8%) subjects had seronegative mumps neutralizing antibody titers and 38 (5.8%) had low titers. One year post-MMR3, these numbers declined to 3 (0.5%) and 16 (2.4%), respectively. Subjects with low baseline titers were more likely to have low 1-month and 1-year titers (R (2) = 0.81-0.87, P < .0001). Compared to baseline, geometric mean titers were significantly higher at 1 month (P < .0001) and 1 year (P < .01) post-MMR3; however, reverse cumulative distribution curves showed only minimal shifts in mumps titers from baseline to 1 month and 1 year. CONCLUSIONS: Very few subjects had negative or low baseline mumps titers. Nonetheless, mumps titers had modest but significant increases when measured 1 month and 1 year post-MMR3. This temporary increase in titers could decrease susceptibility to disease during outbreaks, but may have limited value for routine use in vaccinated populations.

SUBMITTER: Fiebelkorn AP 

PROVIDER: S-EPMC4324223 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mumps antibody response in young adults after a third dose of measles-mumps-rubella vaccine.

Fiebelkorn Amy Parker AP   Coleman Laura A LA   Belongia Edward A EA   Freeman Sandra K SK   York Daphne D   Bi Daoling D   Zhang Cheryl C   Ngo Laurie L   Rubin Steven S  

Open forum infectious diseases 20141018 3


<h4>Background</h4>Mumps outbreaks in populations with high 2-dose measles-mumps-rubella (MMR) vaccine coverage raise the question whether a third dose of MMR vaccine (MMR3) is needed. However, data on the immunogenicity of MMR3 are limited. We assessed mumps virus neutralizing antibody levels pre- and post-MMR3 in a nonoutbreak setting.<h4>Methods</h4>Mumps antibody titers were assessed at baseline, 1 month, and 1 year after MMR3 in subjects aged 18-28 years.<h4>Results</h4>At baseline, 5 of 65  ...[more]

Similar Datasets

| S-EPMC8781586 | biostudies-literature
| S-EPMC5729920 | biostudies-literature
| S-EPMC7731962 | biostudies-literature
| S-EPMC6171567 | biostudies-literature
| S-EPMC9698570 | biostudies-literature
| PRJNA493815 | ENA
| S-EPMC26597 | biostudies-literature
| S-EPMC6992489 | biostudies-literature
| S-EPMC4096048 | biostudies-literature
| S-EPMC4119141 | biostudies-literature